Cardiff Oncology (CRDF) Expected to Announce Earnings on Thursday

Key Points

• Cardiff Oncology (NASDAQ:CRDF) is expected to release its Q2 2025 earnings results on August 14, with analysts predicting a loss of $0.19 per share and $0.10 million in revenue.
• The company's quarterly earnings report on July 29 revealed a loss of $0.21 EPS, falling short of estimates and reflecting a significant negative net margin.
• Investors are closely watching the stock as recent analyst reports have varied widely, with price targets ranging from $3.50 to $19.00 and a current consensus rating of "Moderate Buy."

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Cardiff Oncology to post earnings of ($0.19) per share and revenue of $0.10 million for the quarter.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.11 million. On average, analysts expect Cardiff Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cardiff Oncology Stock Down 0.8%

Shares of NASDAQ:CRDF traded down $0.02 during trading on Friday, hitting $2.39. The stock had a trading volume of 1,231,296 shares, compared to its average volume of 3,188,633. The company has a market capitalization of $159.01 million, a PE ratio of -2.75 and a beta of 1.54. The firm's fifty day moving average is $3.52 and its 200 day moving average is $3.46. Cardiff Oncology has a 12 month low of $2.09 and a 12 month high of $5.64.

Insider Buying and Selling

In other Cardiff Oncology news, Director Gary W. Pace bought 15,000 shares of the business's stock in a transaction on Wednesday, July 30th. The shares were acquired at an average cost of $2.45 per share, for a total transaction of $36,750.00. Following the purchase, the director owned 1,345,676 shares in the company, valued at approximately $3,296,906.20. This trade represents a 1.13% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company's stock.

Institutional Trading of Cardiff Oncology

Several institutional investors have recently added to or reduced their stakes in CRDF. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Cardiff Oncology by 50.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company's stock valued at $108,000 after purchasing an additional 11,497 shares during the last quarter. Rhumbline Advisers boosted its stake in Cardiff Oncology by 18.8% during the 1st quarter. Rhumbline Advisers now owns 63,142 shares of the company's stock valued at $198,000 after purchasing an additional 9,970 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Cardiff Oncology by 7.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company's stock valued at $4,723,000 after purchasing an additional 104,409 shares during the last quarter. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRDF has been the topic of several recent research reports. Jefferies Financial Group initiated coverage on Cardiff Oncology in a research note on Tuesday, June 24th. They issued a "hold" rating and a $3.50 price target on the stock. LADENBURG THALM/SH SH initiated coverage on Cardiff Oncology in a research note on Tuesday, July 8th. They issued a "buy" rating and a $19.00 price target on the stock. William Blair restated an "outperform" rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. Finally, HC Wainwright cut their price target on Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.10.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.